Tirzepatide links to weight loss after surgery, but fat-free-mass data are scarce
A review of five observational studies reported weight loss among adults using tirzepatide after metabolic bariatric surgery. Only one study measured body composition and reported losses in both fat and fat-free mass; the authors rated comparative weight-loss evidence as very low certainty.
A review published November 8 examined tirzepatide use after metabolic bariatric surgery. It included five observational studies of adults who received the drug after surgery.1
Across the studies, mean weight loss ranged from 12% to 18.1% at follow-ups of six to 12 months. Only one study measured body composition; after six months, it reported reductions of 9.5 kilograms in fat mass and 5.5 kilograms in fat-free mass.1
The authors said the evidence was limited and mostly observational; certainty for weight-loss comparisons was very low. For trainers, the single body-composition finding leaves the review unable to show how common fat-free-mass loss was in this group.1
